Company Shares of Progenics Pharmaceuticals (NASDAQ:PGNX) Rally 23.48%

Progenics Pharmaceuticals (NASDAQ:PGNX) : Traders are bullish on Progenics Pharmaceuticals (NASDAQ:PGNX) as it has outperformed the S&P 500 by a wide margin of 16.02% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 21.91%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 23.48% in the last 1 week, and is up 17.89% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The company shares have dropped -28.22% from its 1 Year high price. On Jul 28, 2015, the shares registered one year high at $11.15 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $4.74 and the 200 Day Moving Average price is recorded at $4.74.

The stock has recorded a 20-day Moving Average of 18.76% and the 50-Day Moving Average is 13.4%.


Progenics Pharmaceuticals (NASDAQ:PGNX): stock turned positive on Friday. Though the stock opened at $5.45, the bulls momentum made the stock top out at $5.59 level for the day. The stock recorded a low of $5.38 and closed the trading day at $5.47, in the green by 0.55%. The total traded volume for the day was 1,394,521. The stock had closed at $5.44 in the previous days trading.

In an insider trading activity, Maddon Paul J, director of Progenics Pharmaceuticals Inc had purchased 5,000 shares on December 1, 2010 in a transaction. The price per share was $4.9 and the total amount of the disclosed transaction was $24,500.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Progenics Pharmaceuticals, engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra. PSMA ADC is a human monoclonal antibody-drug conjugate designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein. 1404 (trofolastat) is a radio-labeled small molecule, which binds PSMA and acts as an imaging agent to diagnose and detect prostate cancer. Azedra is a radiotherapeutic product candidate in development as a treatment for pheochromocytoma, a rare tumor found in the adrenal glands, and related paraganglioma tumors occurring in other tissues. The Company also commercializes Relistor, a cure for opioid-induced constipation (OIC).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *